secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001437749-25-029819
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar raises ~$91.9M net in offering; Wilson disease data published in Journal of Hepatology
--------------------------------------------------------------------------------

- Offering of 1,034,433 shares at $67.67 and 960,542 pre-funded warrants at $67.669.
- Net proceeds of ~$91.9M after deducting underwriting discounts and before expenses.
- Agreed to repurchase 550,229 shares from Tactic Pharma (CEO's entity) at $63.6098 per share.
- Journal of Hepatology letter shows ALXN1840 improved copper balance (p=0.005) in Wilson disease patients.
- Offering expected to close September 25, 2025; share repurchase promptly thereafter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925029819/0001437749-25-029819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925029819/mnpr20250924_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer